Universal Biosensors Inc ARBN 121 559 993

1 Corporate Avenue Rowville VIC 3178 Australia

Telephone +61 3 9213 9000 Facsimile +61 3 9213 9099 Email info@universalbiosensors.com www.universalbiosensors.com



21 December 2012

ASX Ltd 20 Bridge Street Sydney NSW 2000

Attention: Simon Daniels

Dear Mr Simon Daniels

# Universal Biosensors, Inc. ("Company") Appendix 3Y's

Enclosed with this letter are three Appendix 3Y's which include disclosures with respect to the acquisition of shares by directors of the Company in the recent share purchase plan.

In preparing the Appendix 3Y's, it has come to the Company's attention that the number of indirect holdings for Dr Wilson was inadvertently understated to ASX although it had been correctly reported to the Securities Exchange Commission (SEC) in the United States. The enclosed Appendix 3Y relating to Dr Wilson addresses this issue.

Likewise, in reconciling the holdings of Mr Denver, we became aware that we had inadvertently not previously reported an indirect change in Mr Denver's holdings to ASX. The enclosed Appendix 3Y relating to Mr Denver addresses this issue.

The Company confirms it has adequate arrangements in place to ensure directors are able to meet their disclosure obligations. Directors are fully apprised of their obligation to notify the Company of any changes in their securityholdings and the Company receives electronic notifications from the Company's registrar of any security transactions involving directors.

Yours sincerely,

Cameron Billingsley Company Secretary

Rule 3.19A.2

# Appendix 3Y

## Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity:	UNIVERSAL BIOSENSORS, INC.
ABN:	121 559 993

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Paul Wright
Date of last notice	6 December 2011

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect Interest	
Nature of indirect interest (including registered holder)  Note: Provide details of the circumstances giving rise to the relevant interest.	Shares of common stock traded in the form of CHESS Depositary Interests (CDIs) acquired by the Macquarie Super Manager of which Paul Martin Wright is a member.	
Date of change	18 December 2012	
No. of securities held prior to change	CDIs held directly: Nil CDIs held indirectly: 28,000 Options over shares of common stock: 2,300,000	
Class	Shares of common stock traded in the form of CDIs	
Number acquired	16,666	
Number disposed	Nil	
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	A\$14,999.40	
No. of securities held after change	CDIs held directly: Nil CDIs held indirectly: 44,666 Options over shares of common stock: 2,300,000	

<sup>+</sup> See chapter 19 for defined terms.

# **Appendix 3Y Change of Director's Interest Notice**

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Subscription for shares of common stock traded in the form of CDIs pursuant to the Universal Biosensors, Inc. Share Purchase Plan.	

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder	
(if issued securities)	
Date of change	
Date of orlange	
No. and class of securities to which	
interest related prior to change	
Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
·	
Interest disposed	
·	
Value/Consideration	
Note: If consideration is non-cash, provide details and	
an estimated valuation	
an estimated valuation	
Interest after change	
interest arter origings	

## Part 3 - +Closed period

Were the interests in the securities or contracts detailed above traded during a *closed period where prior written	N/A
clearance was required?	
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

Appendix 3Y Page 2 01/01/2011

<sup>+</sup> See chapter 19 for defined terms.

Rule 3.19A.2

# Appendix 3Y

# Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity:	UNIVERSAL BIOSENSORS, INC.
ABN:	121 559 993

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Elizabeth Jane Wilson
Date of last notice	30 March 2010

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Change in indirect interest	
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	CHESS Depositary Interests ("CDIs") held by Dr Jane Wilson as trustee for her children.	
Date of change	18 December 2012	
No. of securities held prior to change	CDIs held indirectly: 2,031,500	
Class	Shares of common stock traded in the form of CDIs.	
Number acquired	4,444 CDIs acquired as trustee of behalf of her children.	
Number disposed	Nil.	
Value/Consideration  Note: If consideration is non-cash, provide details and estimated valuation	A\$3,999.60	

<sup>+</sup> See chapter 19 for defined terms.

No. of securities held after change	<ul> <li>2,035,944 CDIs held indirectly as follows:</li> <li>(a) 1,500,000 CDIs held by Warragai Investments Pty Ltd as trustee for the Monteith Trust of which Elizabeth Jane Wilson is a director and potential beneficiary.</li> <li>(b) 500,000 CDIs held Earlston Nominees Pty Ltd as trustee for the Steven Wilson Investment A/c of which Elizabeth Jane Wilson is a director and potential beneficiary.</li> <li>(c) 35,944 held by Elizabeth Jane Wilson as trustee on behalf of her children.</li> </ul>	
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Subscription for shares of common stock traded in the form of CDIs pursuant to the Universal Biosensors, Inc. Share Purchase Plan.	

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change  Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration  Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 - +Closed period

Appendix 3Y Page 2 01/01/2011

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y Change of Director's Interest Notice

Were the interests in the securities or contracts detailed	N/A
above traded during a +closed period where prior written	
clearance was required?	
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

<sup>+</sup> See chapter 19 for defined terms.

Rule 3.19A.2

# Appendix 3Y

## Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity:	UNIVERSAL BIOSENSORS, INC.
ABN:	121 559 993

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Andrew Denver
Date of last notice	13 August 2010

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and indirect interest	
Nature of indirect interest (including registered holder)  Note: Provide details of the circumstances giving rise to the relevant interest.	Shares of common stock traded in the form of CHESS Depositary Interests (CDIs) held by Andrew Denver & Linda Denver as trustees for the Denver Family Superannuation Fund.	
Date of change	(a) 15 May 2012 (b) 16 May 2012 (c) 16 May 2012	
No. of securities held prior to change	CDIs held directly: 1,087,425 CDIs held indirectly: 5,844,580	
Class	Shares of common stock traded in the form of CDIs	
Number acquired	<ul> <li>(a) 678,375 CDIs transferred from direct holding to indirect holding;</li> <li>(b) 664,153 CDIs transferred from spouse to indirect holding; and</li> <li>(c) 12,000 CDIs acquired as indirect holding.</li> </ul>	
Number disposed	678,375 CDIs transferred from direct holding to indirect holding	
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	A\$0.56 per CDI	

<sup>+</sup> See chapter 19 for defined terms.

# **Appendix 3Y Change of Director's Interest Notice**

No. of securities held after change	CDIs held directly: 409,050 CDIs held indirectly: 7,199,108	
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	(a) Off market transfer (b) Off market transfer (c) On market transfer	

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder	
(if issued securities)	
Date of change	
No. and class of securities to which	
interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration	
Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

## Part 3 - +Closed period

Were the interests in the securities or contracts detailed	N/A
above traded during a +closed period where prior written	
clearance was required?	
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

Appendix 3Y Page 2 01/01/2011

<sup>+</sup> See chapter 19 for defined terms.